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Introduction 
Heterocycles  bearing  a  symmetrical  triazole  moiety 
were  reported  to  show  a  broad  spectrum  of 
pharmacological  properties  like  anticancer,
1,2 
antimicrobial,
3-6anticonvulsant,
7  antiinflammatory, 
analgesic
8,9  antidepressant,
10  antitubercular,
11,12 
antimalarial
13  and  hypoglycemic
14  activities.  The 
pyrimidine ring system is a six membered heterocyclic 
ring  structure  composed  of  two  nitrogen  atoms  and 
used  in  the  synthesis  of  pharmaceuticals.  The 
pyrimidine  moiety  is  a  versatile  lead  molecule  in 
pharmaceutical development and has a wide range of 
biological  activities.  In  the  past  few  years,  the 
therapeutic  interest  of  pyrimidine  derivatives  in 
pharmaceutical  and  medicinal  field  has  been  given  a 
great  attention  to  the  medicinal  chemist.  Literature 
survey  reveals  that  pyrimidine  derivatives  are  well 
known  to  have  antimicrobial,
15-17  antimalarial,
18 
anticonvulsant,
19  anticancer,
20  antiinflammatory, 
analgesic,
21,22    antitubercular
23  activities.  In  recent 
years,  the  extensive  studies  have  been  focused  on 
pyrimidine  derivatives  because  of  their  diverse 
chemical  reactivity,  accessibility  and  wide  range  of 
biological activities. We have recently reported the in 
vitro  antimicrobial  potential  of  1-(3,5-diphenyl-1H-
1,2,4-triazol-1-yl)-3-(substituted  aryl)  prop-2-en-1-one 
(chalcones)  and  MIC  values  of  different  derivatives 
were determined by liquid broth method.
24 
The  widespread  properties  of  1,2,4-triazoles  and 
pyrimidines  have  prompted  us  to  synthesize  them  in 
single  molecular  framework  in  order  to  study  their 
pharmacological  activity.  Hence,  the  present 
investigation  was  undertaken  to  study  the 
antimicrobial,  anticonvulsant  and  antitumorpotential 
ofpyrimidine  derivatives  containing  1,2,4-triazole 
moiety. In this dissertation, we achieved the successful 
synthesis and  significant  antimicrobial,  anticonvulsant 
and  anticancer  potential  of  a  series  of  6-(substituted 
aryl)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-1,6-
dihydropyrimidine-2-thiol (4a-j). 
 
Materials and methods 
The chemicals and solvents used for the experimental 
work were commercially procured from E. Merck India 
and  Qualigens  India.  The  melting  points  of  all 
synthesized compounds were determined by open tube 
capillary  using  Thermonik  precision  apparatus  in 
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Purpose: An efficient method has been described for synthesis of 6-(substituted aryl)-4-
(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-1,  6-dihydropyrimidine-2-thiol,  as  a  beneficial 
antimicrobial,  anticonvulsant  and  anticancer  agents.  Methods:  The  clalcones  of  title 
compounds  were  synthesized  in  three  steps  and  subsequently  these  chalcones  were 
further  reacted  with  thiourea  in  the  presence  of  KOH  in  ethanol,  which  led  to  the 
formation of dihydropyrimidine derivatives (4a-j). Compounds 4a-j were screened for 
their in vitro antimicrobial activity by agar well method and their anticonvulsant activity 
by  the  MES  model.  Anticancer  activity  of  two  newly  synthesized  heterocycles  were 
evaluated at National Cancer Institute (NCI) Maryland, USA against 60 cell lines of 
different human tumor at a single dose of 10
-5M. Results: Compound 4b, 4c, 4d, 4i and 
4j were exhibited significant antimicrobial potential against tested strains at 50μg/ml and 
100μg/ml  concentrations.  Out  of  the  ten  compounds  studied  4a,  4b,  4c,  4h  and  4j 
showed comparable MES activity to Phenytoin and Carbamazepine after 0.5h. Tested 
compounds did not showed to be more potent than standard drugs after 4h. Compound 
4a and 4d were found active on Non-Small Cell Lung Cancer (HOP-92). Conclusion: 
Ten noveldihydropyrimidine analogues has been synthesized, characterized and found to 
bepromising antibacterial, anticonvulsant and antitumor agents.  
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Celsius scale and uncorrected. IR spectra were recorded 
using  KBr  pellets  on  PERKIN  ELMER  8201  PC  IR 
spectrophotometer, 
1H-NMR  spectra  of  the  final 
compounds  4a-j  were  recorded  on  BRUKER  DRX 
NMR  spectrometer  (400  MHz).  All  spectra  were 
obtained  in  DMSO.  Mass  spectra  (FAB-MS)  of 
compounds 4a-j were recorded on 70V on JEOL D-300 
spectrophotometer (Jeol Ltd., Tokyo, Japan). Elemental 
analysis for C, H and N were performed on a PERKIN 
ELMER 240 elemental analyzer. 
 
Synthesis protocol 
Compounds 1, 2, and 3a-j were synthesized according 
to the reported method.
24 
 
Synthesis of 3,5-diphenyl-1H-1,2,4-triazole (1) 
Benzohydrazide (0.1 mole) was dissolved in methanol, 
to this solution benzamide (0.1 mole) was added and 
stirred to get clear solution, then the resulting reaction 
mixture  was  refluxed  for  two  hours  on  water  bath. 
Therafter  the  reaction  mixture  was  cooled  at  room 
temperature  and  poured  in  ice  cold  water  to  get 
precipitated  3,5-diphenyl-1H-1,2,4-triazole.  Then 
obtained product was recrystallized by dioxane:ethanol 
mixture with an yield 83 %, m.p. 196-198
°C. 
 
Synthesis  of  1-(3,5-diphenyl-1H-1,  2,  4-triazol-1-yl) 
ethanone (2) 
To a solution of compound 1 (0.05 mole) dissolved in 
methanol, acetic anhydride (0.05 mole) and 2-3 drops 
of  concentrated  sulfuric  acid  were  added,  then  the 
resulting reaction mixture was warmed on a water bath 
for 20 min. The reaction mixture was cooled at room 
temperature  and  poured  in  to  ice  cold  water  to  get 
precipitate  of  compound  2.  The  precipitate  of 
compound 2 was purified by dioxane:ethanol mixture 
with an yield 76 %, m.p. 176-178
°C. 
 
General  procedure  for  synthesis  of  1-(3,5-diphenyl-
1H-1,2,4-triazol-1-yl)-3-(substituted  aryl)  prop-2-en-
1-one(Chalcones) 3a-j 
Compound 2 (0.05 mole) in methanol was treated with 
substituted aromatic aldehydes (0.05 mole) and 20% 10 
ml NaOH, afterward stirred the reaction mixture for 7-8 
hours at room temperature. The mixture was poured in 
ice  cold  water  to  get  precipitate  of  compounds  3a-j, 
subsequently recrystallized by dioxane:ethanol mixture.  
 
General  procedure  for  synthesis  of  6-(substituted 
aryl)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-1,6-
dihydropyrimidine-2-thiol (4a-j) 
A mixture of 0.01 mole of the required chalcones (3a-
j), 0.01 mole thiourea and KOH (1gm) in 20 ml ethanol 
was heated under reflux for 6 hours, then cooled and 
poured on to crushed ice. The solid product obtained 
was  filtered  and  recrystallized  from  dioxane:ethanol 
mixture.  
Physical and spectral data of the compounds 4a-j are 
mentioned bellow. 
Physical and spectral data of compounds 4a-j. 
6-(4-chlorophenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-
1-yl)-1,6-dihydropyrimidine-2-thiol (4a). 
Yield 67 %, m.p. 120-122
°C. Elemental analysisFound 
C  64.89;  H  4.02;  N  15.70,  Calculated  for 
(C24H18ClN5S), C 64.93; H 4.09; N 15.78.IR(KBr, cm
–
1): 2940, 3075, 3151 (Ar-CH), 1629 (C=N, triazole), 
1415  (C=C,  pyrimidine),  787  (-Cl),  2626  (-SH).  MS 
m/z: 443(M
+). 
1H NMR (400 MHZ, DMSO) δ: 7.69-
8.40 (14H, m, Ar-H), 4.46 (d, 1H, NH-CH), 5.92 (d, 
1H, CH), 13.39 (S, 1H, Ar-SH), 5.27 (s, 1H, NH). 
 
6-(2-chlorophenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-
1-yl)-1,6-dihydropyrimidine-2-thiol(4b).  
Yield 71 %, m.p. 125-127
°C. Elemental analysisFound 
C  64.84;  H  4.12;  N  15.72,  Calculated  for 
(C24H18ClN5S), C 64.93; H 4.09; N 15.78.IR(KBr, cm
–
1): 2939, 3073, 3175 (Ar-CH), 1624 (C=N, triazole), 
1419  (C=C,  pyrimidine),  779  (-Cl),  2616  (-SH).  MS 
m/z: 443(M
+). 
1H NMR (400 MHZ, DMSO) δ: 7.65-
8.47(14H,  m,  Ar-H),  4.48  (d,  1H,  NH-CH),  5.94  (d, 
1H, CH), 13.41 (S, 1H, Ar-SH), 5.25 (s, 1H, NH). 
 
6-(3-nitrophenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-
yl)-1,6-dihydropyrimidine-2-thiol(4c). 
Yield 65 %, m.p. 107-109
°C. Elemental analysisFound 
C  63.44;  H  4.06;  N  18.40,  Calculated  for 
(C24H18N6O2S), C 63.42; H 3.99; N 18.49.IR(KBr, cm
–
1): 2942, 3078, 3180 (Ar-CH), 1628 (C=N, triazole), 
1417 (C=C, pyrimidine), 1551 (-NO2), 2619 (-SH). MS 
m/z: 454(M
+). 
1H NMR (400 MHZ, DMSO) δ: 7.64-
8.38 (14H, m, Ar-H), 4.45 (d, 1H, NH-CH), 5.96 (d, 
1H, CH), 13.44 (S, 1H, Ar-SH), 5.26 (s, 1H, NH). 
 
6-(4-methoxyphenyl)-4-(3,5-diphenyl-1H-1,2,4-
triazol-1-yl)-1,6-dihydropyrimidine-2-thiol(4d). 
Yield 68 %, m.p. 130-132
°C. Elemental analysisFound 
C  68.33;  H  4.82;  N  15.83,  Calculated  for 
(C25H21N5OS), C 68.32; H 4.82; N 15.93.IR(KBr, cm
–
1): 2947, 3075, 3181 (Ar-CH), 1625 (C=N, triazole), 
1415  (C=C,  pyrimidine),  1159  (-OCH3),  2618  (-SH). 
MS  m/z:  439(M
+). 
1H  NMR  (400  MHZ,  DMSO)  δ: 
7.64-8.38 (14H, m, Ar-H), 4.44(d, 1H, NH-CH), 5.96 
(d,  1H,  CH),  13.55  (S,  1H,  Ar-SH),  3.82  (3H,  s, 
OCH3),5.27 (s, 1H, NH). 
 
6-(4-dimethylaminophenyl)-4-(3,5-diphenyl-1H-1,2,4-
triazol-1-yl)-1,6-dihydropyrimidine-2-thiol(4e).  
Yield 74 %, m.p. 140-142
°C. Elemental analysisFound 
C 69.06; H 5.33; N 18.57, Calculated for (C26H24N6S), 
C 69.00; H 5.35; N 18.57.IR(KBr, cm
–1): 2939, 3076, 
3174  (Ar-CH),  1623  (C=N,  triazole),  1412  (C=C, 
pyrimidine),  3159,  3146  (-NCH3),  2606  (-SH).  MS 
m/z: 452(M
+). 
1H NMR (400 MHZ, DMSO) δ: 7.61-8. 
56 (14H, m, Ar-H), 4.47(d, 1H, NH-CH), 5.90 (d, 1H, 
CH), 13.49 (S, 1H,  Ar-SH), 3.19 (6H, s,  -N(CH3)2), 
5.23 (s, 1H, NH). 
  
|215 
Pharmacological activities of some new pyrimidine derivatives 
Advanced Pharmaceutical Bulletin, 2012, 2(2), 213-222  Copyright © 2012 by Tabriz University of Medical Sciences 
6-(phenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-1,6-
dihydropyrimidine-2-thiol (4f). 
Yield 72 %, m.p. 115-117
°C. Elemental analysisFound 
C 70.36; H 4.60; N 17.19, Calculated for (C24H19N5S), 
C 70.39; H 4.68; N 17.10.IR(KBr, cm
–1): 2946, 3072, 
3182  (Ar-CH),  1621  (C=N,  triazole),  1411  (C=C, 
pyrimidine), 2609 (-SH). MS m/z: 409(M
+). 
1H NMR 
(400 MHZ, DMSO) δ: 7.56-8.39 (15H, m, Ar-H), 4.45 
(d, 1H, NH-CH), 5.93 (d, 1H, CH), 13.61 (S, 1H, Ar-
SH), 5.29 (s, 1H, NH).  
 
6-(2-furul)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-1,6-
dihydropyrimidine-2-thiol(4g).  
Yield 68 %, m.p. 111-123
°C. Elemental analysisFoundC 
66.12; H 4.34; N 17.44, Calculated for (C22H17N5OS), C 
66.15; H 4.29; N 17.53.IR(KBr, cm
–1): 2942, 3079, 3178 
(Ar-CH), 1628 (C=N, triazole), 1416 (C=C, pyrimidine), 
1224 (C-O-C), 2611 (-SH). MS m/z: 399(M
+). 
1H NMR 
(400 MHZ, DMSO) δ: 7.06-8. 37 (13H, m, Ar-H), 4.46 
(d, 1H, NH-CH), 5.97(d, 1H,  CH), 13.47 (S, 1H,  Ar-
SH), 5.28 (s, 1H, NH). 
 
6-(4-bromophenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-
1-yl)-1,6-dihydropyrimidine-2-thiol(4h). 
Yield 58 %, m.p. 117-119
°C. Elemental analysisFound 
C  59.04;  H  3.67;  N  14.39,  Calculated  for 
(C24H18BrN5S), C 59.02; H 3.71; N 14.34.IR(KBr, cm
–
1): 2936, 3066, 3173 (Ar-CH), 1625 (C=N, triazole), 
1413  (C=C,  pyrimidine),  698  (-Br),  2615  (-SH).  MS 
m/z: 488(M
+). 
1H NMR (400 MHZ, DMSO) δ: 7.55-
8.48 (14H, m, Ar-H), 4.47 (d, 1H, NH-CH), 5.94 (d, 
1H, CH), 13.38 (S, 1H, Ar-SH), 5.27 (s, 1H, NH). 
 
6-(4-hydroxyphenyl)-4-(3,5-diphenyl-1H-1,2,4-triazol-
1-yl)-1,6-dihydropyrimidine-2-thiol(4i). 
Yield 72 %, m.p. 127-129
°C. Elemental analysisFoundC 
67.79; H 4.49; N 16.42, Calculated for (C24H19N5OS), C 
67.74; H 4.50; N 16.46.IR(KBr, cm
–1): 2946, 3073, 3175 
(Ar-CH), 1622 (C=N, triazole), 1412 (C=C, pyrimidine), 
3357 (-OH), 2616 (-SH). MS m/z: 425(M
+). 
1H NMR 
(400 MHZ, DMSO) δ: 7.48-8.59 (14H, m, Ar-H), 4.49 
(d, 1H, NH-CH), 5.96 (d, 1H, CH), 13.41 (S, 1H, Ar-SH), 
10.16 (s, 1H, Ar-OH), 5.26 (s, 1H, NH). 
 
6-(2,4-dimethoxyphenyl)-4-(3,5-diphenyl-1H-1,2,4-
triazol-1-yl)-1,6-dihydropyrimidine-2-thiol(4j). 
Yield 65 %, m.p. 133-135
°C. Elemental analysisFound C 
66.59; H 4.89; N 14.92, Calculated for (C26H23N5O2S), C 
66.50; H 4.94; N 14.91.IR(KBr, cm
–1): 2941, 3079, 3186 
(Ar-CH), 1624 (C=N, triazole), 1416 (C=C, pyrimidine) 
1155 (-OCH3), 2626 (-SH). MS m/z: 469(M
+). 
1H NMR 
(400 MHZ, DMSO) δ: 7.31-8.44 (13H, m, Ar-H), 4.45 
(d, 1H, NH-CH), 5.95 (d, 1H, CH), 13.39 (S, 1H, Ar-SH), 
3.89 (6H, s, OCH3), 5.28 (s, 1H, NH). 
 
Pharmacological assessment 
Antimicrobial Activity 
The  in  vitro  antimicrobial  activity  of  the  target 
compounds  4a-j  was  performed  by  agar  well  method 
(diffusion technique) against S. aureus NCIM 2079, E. 
coli NCIM 2065, C. albicans NCIM 3471 and A. niger 
NCIM  1196.  The  antibiotic  Ampicillin  and  the 
antifungal  agent  Fluconazole  were  used  as  standard 
drugs  for  the  study.  The  fresh  bacterial  culture  was 
obtained  by  inoculating  bacteria  into  peptone  water 
liquid  media  and  incubating  at  37±  2 
°C  for  18-24 
hours. This culture was mixed with nutrient agar media 
and  poured  in  to  Petri  dishes.  After  culture  media 
solidification four wells were made at equal distance by 
using a sterile steel cork borer (8mm diameter). In to 
these  wells  different  concentrations  of  standard  drug 
and synthesized compounds were introduced. Dimethyl 
Formamide  (DMF)  was  used  as  a  control.  After 
introduction  of  standard  drug  and  synthesized 
compounds, the plates were placed in a refrigerator at 
8-10 
°C for proper diffusion of drugs into the media. 
After  two  hours  of  cold  incubation,  the  Petri  plates 
were transferred to incubator and maintained at 37±2 
°C  for  18-24  hours.  After  the  incubation  period,  the 
petri plates were observed for growth inhibition zone 
by using vernier scale. The results were evaluated by 
comparing  the  growth  inhibition  zone  shown  by  the 
synthesized  compounds  with  standard  drugs.  The 
results  were  presented  as  the  mean  value  of  growth 
inhibition  zone  measured  in  millimeters  of  three  sets 
(Table  1).  The  standard  drugs  and  synthesized 
compounds were dissolved in a minimum quantity of 
Dimethyl Formamide (DMF) and adjusted, to made up 
the  volume  with  distilled  water  to  get  50μg/ml  and 
100μg/ml concentrations. 
 
Anticonvulsant  Activity:  Maximal  Electroshock 
Seizure Test (MES) 
The  compounds  4a-j  were  screened  for  their 
anticonvulsant  activity  by  Maximal  electroshock 
seizure  method.  Study  protocol  was  approved  by  the 
Institutional Animal Ethics Committee for the purpose 
of control and supervision on experiments on animals 
(IAEC,  Approval  No.1211/ac/08/CPCSEA)  before 
experiment.  Initial  anticonvulsant  evaluations  of  the 
test  compounds  were  undertaken  by  following  the 
anticonvulsant  drug  development  (ADD)  program 
protocol.
25 The animals Albino mice (20-25 g) of either 
sex were stimulated  through corneal  electrodes to  50 
mA  current  at  a  pulse  of  60  Hz  applied  for  0.2  s. 
Animals  were  previously  given  the  test  drug 
intraperitoneally.  Abolition  of  the  hind  limb  tonic 
extension  spasm  was  recorded  as  the  anticonvulsant 
activity. The test compounds were suspended in a 0.5% 
methyl  cellulose-water  mixture.  In  preliminary 
screening,  each  compound  was  administered  through 
an intraperitoneally injection at three dose levels (30, 
100 and 300 mg/kg) and the anticonvulsant activity was 
assessed after 0.5 h and 4 h intervals of administration. 
The  anticonvulsant  efficacy  was  evaluated  by  the 
maximal  electroshock-induced  seizure  (MES)  and 
screening  data  of  compounds  4a-j  are  presented  in 
Table 2.  
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Table 1. Antimicrobial activity of compounds 4a-j. 
Compound 
                           Zone of inhibition (in mm) 
S. aureus  E. coli  C. albicans  A. niger 
50μg  100μg  50μg  100μg  50 μg  100μg  50 μg  100μg 
4a  19  21  18  23  20  23  18  21 
4b  18  21  19  23  22  25  23  22 
4c  21  24  24  24  19  22  18  23 
4d  19  22  19  22  23  22  22  21 
4e  18  19  17  20  20  21  19  20 
4f  15  17  14  17  18  19  16  18 
4g  16  19  17  20  15  19  17  21 
4h  19  21  21  19  19  22  21  19 
4i  21  19  22  20  21  18  22  22 
4j  22  21  20  20  19  18  16  19 
Ampicillin  21  25  24  26  -  -  -  - 
Fluconazole  -  -  -  -  24  26  23  25 
DMF  -  -  -  -  -  -  -  - 
 
 
Table 2. Anticonvulsant and neurotoxicity screening of compounds 4a-j. 
Sr. No.   Treatment  Ar  
MES screen
a   Neurotoxicity screen
a  
0.5h   4h   0.5h   4h  
1   4a  4-Cl  30   300   300   _  
2   4b  2-Cl  30   300   _   300  
3   4c  3-NO2  30   300   _   _  
4   4d  4-OCH3  100   300   300   300  
5   4e  4-N(CH3)2  100   300   _   300  
6   4f  phenyl  100   300   300   300  
7   4g  2-Furyl  100   300   _   _  
8   4h  4-Br  30   300   300   300  
9   4i  4-OH  100   300   _   300  
10   4j  2,4-OCH3  30   300   _   _  
11   Phenytoin  _  30   30   100   100  
12   Carbamazepine  _  30   100   300   300  
 “a” Doses of 30, 100 and 300 mg/kg were administered. The figures in the Table indicate the minimum dose whereby bioactivity was 
demonstrated in half or more of mice. The animals were examined 0.5 and 4 h after injections were given. The dash “-“ indicates an 
absence of activity at maximum dose administered (300 mg/kg). 
 
Neurotoxicity screening (NT)  
The minimal motor impairment was measured in mice 
by the rotorod test.
26 The Albino mice (20-25 g) were 
trained to stay on an accelerating rotorod that rotated at 
10  rotations/min  and  its  diameter  was  3.2  cm.  Only 
those mice were taken for the test which could stay on 
the  revolving  rod  for  at  least  one  minute.  Trained 
animals  were  injected  intraperitoneally  with  the  test  
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compounds at doses of 300 mg/kg. Neurotoxicity was 
indicated  by  the  inability  of  the  animal  to  maintain 
equilibration on the rod for at least for one minute. 
 
Anticancer activity 
Anticancer activity  of newly  synthesized  heterocycles 
were  evaluated.  Primarily  compounds  submitted  at 
National  Cancer  Institute  (NCI)  Maryland,  USA 
andselected  compounds  were  screened  for  anticancer 
activity against 60 cell lines of different human tumor, 
representing  leukemia,  melanoma  and  cancers  of  the 
lung, colon, brain, ovary, breast, prostate, and kidney 
for one dose against the 60 cell lines at a single dose of 
10
-5M. The mean growth %,  range of growth %  and 
growth % relative to most sensitive cell line is depicted 
in Table 3. 
 
Results and discussion 
The  synthesis  of  6-(substituted  aryl)-4-(3,5-diphenyl-
1H-1,2,4-triazol-1-yl)-1,6-dihydropyrimidine-2-thiol 
derivatives (4a-j)depicted in Figure 1. The compound1-
(3,5-diphenyl-1H-1,2,4-triazol-1-yl)ethanone  (2)  on 
condensation with various aromatic aldehydes in NaOH 
solution  yielded  the  corresponding  chalcones  (3a-j). 
These chalcones were further reacted with thiourea in 
the  presence  of  KOH  in  ethanol,  which  led  to  the 
formation  of  dihydropyrimidine  derivatives  (4a-j) 
(Figure  2).  The  structural  assessments  of  compounds 
4a-j were carried out by IR, 
1H-NMR, Mass spectra and 
elemental analysis.Structures of compounds 4a-j were 
confirmed  IR, 
1H-NMR,  mass  spectra  and  elemental 
analysis. Infrared spectrum of compounds 4a-j showed 
a  sharp  absorption  band  frequencies  for-NO2,  -Cl,  -
OCH3,  -N-(CH3)2,  -OH  and  -Br  groups.  Compounds 
4a-j showed appropriate 
1H-NMR signals for aromatic 
protons and multiplets were observed in the range of δ 
7.06-8.59. The 
1H NMR spectra showed a downfield 
singlet  at  around  13.4  ppm  attributed  to  SH  group. 
Mass spectraof the compounds 4a-j showed molecular 
ion  peaks  with  high  abundance  at  m/z  in  agreement 
with  their  molecular  formula.  Compounds  4a-j 
evaluated  for  their  in  vitro  antimicrobial, 
anticonvulsant and anticancer activity. 
 
Table 3. Anticancer screening data of selected compounds. 
Compound No.  60 Cell lines in assay in 1-dose 10 
-5 M concentration 
(NSC code) 
Mean growth 
(%) 
Range growth 
(%) 
Most sensitive 
cell line 
Growth of most 
sensitive cell line (%) 
4a 
(764753/1) 
106.85  -27.71-55.23 
Non-Small Cell 
Lung Cancer 
(HOP 92) 
- 27.71 
4d 
(764754/1) 
103.26  -19.05-50.25 
Non-Small Cell 
Lung Cancer 
(HOP 92) 
-19.05 
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Figure 1. Synthesis of compounds 4a-j. 
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The in vitro antimicrobial activity of tested compounds 
was determined by agar well method. The results are 
summarized  in  Table  1.  These  antimicrobial  data 
clearly indicated that the presence of methoxy, chloro, 
nitro  and  hydroxysubstitution  on  phenyl  ring  of  the 
pyrimidine nucleus produced remarkable improvement 
in antimicrobial activity. Phenyl substitution is weakly 
active among the synthesized compounds.  Compound 
4c  showed  significant  antibacterial  activity  against  S. 
aureus and E. coli.  Compound 4b showed  fungicidal 
potential against C. albicans and A. niger. The in vitro 
antimicrobial  study  clearly  reveals  that  pyrimidine 
derivatives  (4a-j)  were  found  to  be  significant 
antimicrobial agents probably due to pharmacologically 
active pyrimidine nucleus attached with 1,2,4-triazole. 
The  target  compounds  (4a-j)  were  tested  for 
anticonvulsant  activity  by  maximal  electroshock 
induced  seizure  (MES)  test.  The  anticonvulsant  and 
neurotoxicity  data  of  the  compounds  and  standard 
drugs  are  presented  in  Table  2.  The  compounds  that 
exhibited  the  most  potent  anti-MES  activity  included 
4a, 4b, 4c, 4h and 4j which have activity comparable 
with  Phenytoin  and  Carbamazepine.  Minimal  motor 
impairment  was  measured  by  the  rotorod  test. 
Compounds  4c,  4g,  and  4j  successfully  passed  the 
rotorod  test  without  any  sign  of  neurological  deficit, 
whereas  compounds  4d,  4f  and  4h  exhibited 
neurological  deficit  at  the  dose  of  300  mg/kg  i.p. 
Compounds  with  the  electron  withdrawing  chloro 
substituent at the ortho and para position and bromo at 
para position on the phenyl ring of pyrimidine nucleus 
led  to  considerable  increase  in  the  activity  but  were 
relatively  toxic.  The  presence  of  a  bulkier  electron 
donating methoxy group at para and ortho position on 
the phenyl ring of pyrimidine nucleus results increase 
in  anticonvulsant  activity.  This  may  be  due  to  the 
increase  in  lipophilicity  of  the  compound.  The  nitro 
substituent  at  the  meta  position  of  the  phenyl  ring 
found to be equally active with chloro substitution but 
without sign of neurotoxity. The effect of the hydroxy, 
phenyl  and  furyl  substitution  were  found  to  be  less 
active  compounds  as  compared  to  other  tested 
compounds.  
The  compounds  4a  and  4d  were  evaluated  at  single 
concentration  of  10
-5  M  towards  the  panel  of 
approximately 60 cancer cell lines derived from nine 
different cancer types. The mean growth %, range of 
growth % and growth % relative to most sensitive cell 
line  is  depicted  in  Table  3.  The  tested  compounds 
showed a broad spectrum of growth inhibitory activity 
against human tumor cells, as well as some distinctive 
pattern  of  selectivity  (Figure  3  and  Figure  4). 
Compound 4a was found to be a highly active growth 
inhibitor of the Non-Small Cell Lung Cancer (HOP-92) 
and CNS Cancer cell line (SNB-75) with a growth % of 
most sensitive cell line to be - 27.71, whilst least active 
over  other  cell  lines.  The  mean  growth  %  for 
compound 4a was observed 106.85% and fall in a range 
-  27.71-55.23.  Compound  4d  showed  selective 
antitumor sensitivity on Non-Small Cell Lung Cancer 
(HOP-92)  and  renal  Cancer  cell  line  (A498)  with  a 
growth  %  of  most  sensitive  cell  line  to  be  -19.05, 
whilst  least  active  over  other  cell  lines.  The  mean 
growth % for compound 4d was observed 103.26% and 
fall in a range -19.05-50.25. 
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Figure 2. The possible mechanism involved in the formation of dihydropyrimidine derivatives (4a-j)from the respective chalcones is 
shown above.  
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Figure 3. Selected NCI sixty cell screening data highlighting the potency of compound (4a: NSC: 764753/1) againstnon-Small 
Cell Lung Cancer (HOP-92) and CNS Cancer cell line (SNB-75). Bars to the right of the mean line represent cell lines more 
sensitive to test compound compared to mean, whereas bars to the left represent less sensitive cell lines. 
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Figure 4. Selected NCI sixty cell screening data highlighting the potency of compound (4d: NSC: 764754/1) againstnon-Small Cell Lung 
Cancer (HOP-92) and renal Cancer cell line (A498). Bars to the right of the mean line represent cell lines more sensitive to test 
compound compared to mean, whereas bars to the left represent less sensitive cell lines. 
 
Conclusion 
In  conclusion,  new  class  of  pyrimidine  derivatives 
containing 1,2,4-triazole was synthesized and evaluated 
as  antimicrobial,  anticonvulsant  and  anticancer 
properties.  The  newly  synthesized  heterocycles 
exhibited  promising  antimicrobial  activity  against 
tested microorganisms. Compounds 4b, 4c, 4d, 4i and 
4j  were  found  to  be  the  most  active  antimicrobial  
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agents  from  synthesized  series.  From  the 
anticonvulsant screening data  it was found  that of  6-
(substituted  aryl)-4-(3,5-diphenyl-1H-1,2,4-triazol-1-
yl)-1,6-dihydropyrimidine-2-thiol  derivatives  (4a-j) 
have  encouraging  anticonvulsant  activity  in  the  MES 
screen. Compound 4a, 4b, 4c, 4h and 4j found to be 
effective anticonvulsant agent from tested compounds. 
In the present study two compounds (4a and 4d) were 
tested  for  anticancer  activity  and  most  of  them 
displayed antitumor activity on cell lines of Non-Small 
Cell Lung Cancer, CNS Cancer and renal Cancer.These 
results  suggest  that  novel  triazolechalcones  and 
pyrimidine  derivatives  are  interesting  lead  molecules 
for further synthetic and biological evaluation. 
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